This Article Full Text Full Text (PDF) All Versions of this Article: 40/1/213    most recent STROKEAHA.108.522193v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kettani, F.-Z. Articles by Perreault, S. Search for Related Content PubMed PubMed Citation Articles by Kettani, F.-Z. Articles by Perreault, S. Related Collections Primary prevention Cerebrovascular disease/stroke Epidemiology

(Stroke. 2009;40:213.)
© 2009 American Heart Association, Inc.

Original Contributions

Impact of a Better Adherence to Antihypertensive Agents on Cerebrovascular Disease for Primary Prevention

Fatima-Zohra Kettani, MSc; Alice Dragomir, MSc; Robert Côté, MD, FRCPC; Louise Roy, MD, FRCPC; Anick Bérard, PhD; Lucie Blais, PhD; Lyne Lalonde, PhD; Pierre Moreau, PhD Sylvie Perreault, PhD

From the Faculty of Pharmacy (F.-Z.K., A.D., A.B., L.B., L.L., P.M., S.P.), University of Montréal, Montréal, Canada; the Faculty of Medicine (R.C.), McGill University, Montréal, Québec, Canada; and the Faculty of Medicine (L.R.), University of Montréal, Montréal, Québec, Canada.

Correspondence to Sylvie Perreault, PhD, Faculty of Pharmacy, PO Box 6128, Centre-Ville Station, Montréal, Québec, Canada H3C 3J7. E-mail sylvie.perreault{at}umontreal.ca

Background and Purpose— The benefits of antihypertensive (AH) drugs on the risks of major cardiovascular outcomes have been demonstrated in clinical trials. However, approximately half of hypertensive patients do not adhere well to their prescribed AH therapy in actual practice. The purpose of this study was to assess the impact of adherence to AH agents on the incidence of cerebrovascular disease (CD) in real-world practice.

Methods— A cohort of 83 267 hypertensive patients was reconstructed from the Régie de l’assurance maladie du Québec databases. Subjects included were between 45 and 85 years old, initially free of cardiovascular disease, and newly treated for hypertension with AH agents between 1999 and 2004. A nested case–control design was conducted to study CD occurrence. Every case was matched for age and duration of follow-up with up to 15 randomly selected control subjects. The adherence to AH drugs was measured by calculating the medication possession ratio. Conditional logistic regression models were performed to assess the association between adherence to AH agents and CD adjusting for various potential confounders.

Results— At cohort entry, the mean patient age was 65 years, 37.3% were male, 8.6% had diabetes, and 19.5% had dyslipidemia. High adherence (80%) to AH drugs significantly decreased the risk of CD by 22% (rate ratio, 0.78; 95% CI, 0.70 to 0.87) compared with lower adherence. Male gender, occurrence of cardiovascular disease during follow-up, and dyslipidemia were risk factors for CD.

Conclusion— High adherence to AH therapy is associated with a reduced risk of CD outside the context of clinical trials in primary prevention.

Key Words: adherence to treatment • antihypertensive drugs • cerebrovascular disease